{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:24:51Z","timestamp":1770967491088,"version":"3.50.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260798,  82460802, 82260914"],"award-info":[{"award-number":["82260798,  82460802, 82260914"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thrombopoietin receptor agonists (TPO-RA) are widely used for immune thrombocytopenia (ITP), but their post-marketing thromboembolic safety profiles and onset patterns remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAERS reports from January 2009 to December 2024 were cleaned to remove duplicates and non-suspected roles, yielding 2,092 unique thromboembolic AE cases. TPO-RA exposure was identified by generic and brand names. Disproportionality analyses employed reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN). Time-to-onset analysis and logistic regression (univariate and multivariate) examined demographic and treatment factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Avatrombopag, Eltrombopag, and Romiplostim yielded 105, 1,044, and 943 thromboembolic AE reports, respectively. Pulmonary embolism, deep vein thrombosis, and portal vein thrombosis predominated with Avatrombopag; Eltrombopag and Romiplostim were mainly associated with pulmonary embolism, deep vein thrombosis, and acute myocardial infarction. Avatrombopag showed the strongest ROR signal for renal vein thrombosis (ROR = 136.49; 95% CI: 56.53\u2013329.56), while Eltrombopag and Romiplostim exhibited highest signals for renal embolism (ROR = 23.70; 95% CI: 8.78\u201364.00) and arterial embolism (ROR = 37.63; 95% CI: 25.68\u201355.14), respectively. Median time to onset was 81 days (IQR: 25\u2013263), with 25% of events occurring within 25 days. Multivariate analysis identified age &amp;gt; 85 years (OR = 14.94; 95% CI: 12.51\u201317.97), body weight &amp;gt; 100 kg (OR = 1.43; 95% CI: 1.26\u20131.63), and treatment duration &amp;gt; 730 days (OR = 1.32; 95% CI: 1.21\u20131.45) as independent factors associated with increased reporting odds of thromboembolic events. Compared with Avatrombopag, Eltrombopag (OR = 0.32; 95% CI: 0.25\u20130.40) and Romiplostim (OR = 0.20; 95% CI: 0.16\u20130.25) were associated with lower reporting odds of thromboembolic AE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Real-world pharmacovigilance evidence indicates that thromboembolic event reporting for TPO-RAs shows drug-specific patterns, with venous events predominating and a notable fraction occurring early after treatment initiation. Patients of very advanced age, those with higher body weight, and those receiving prolonged therapy appear particularly vulnerable, supporting proactive baseline risk stratification and sustained thrombosis surveillance throughout treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1669486","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:39:49Z","timestamp":1770964789000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Thromboembolic adverse events associated with TPO-RA in ITP treatment: a pharmacovigilance analysis of the FDA Adverse Event Reporting System"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhen","family":"Lu","sequence":"first","affiliation":[{"name":"Jiangxi University of Chinese Medicine","place":["Nanchang, China"]},{"name":"The Affiliated Hospital of Jiangxi University of Chinese Medicine","place":["Nanchang, China"]},{"name":"Research Center for Differentiation and Development of Basic Theory of Traditional Chinese Medicine","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjian","family":"Zeng","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Jiangxi University of Chinese Medicine","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangbin","family":"Shang","sequence":"additional","affiliation":[{"name":"Research Center for Differentiation and Development of Basic Theory of Traditional Chinese Medicine","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Chinese Medicine, Jiangxi University of Chinese Medicine","place":["Nanchang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012541","article-title":"The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia","volume":"8","author":"Neunert","year":"2024","journal-title":"Blood Adv"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19489","article-title":"Comprehensive analysis and prediction model of mitophagy and ferroptosis in primary immune thrombocytopenia","volume":"204","author":"Mo","year":"2024","journal-title":"Br J Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1499014","article-title":"The function of T cells in immune thrombocytopenia","volume":"16","author":"Bu","year":"2025","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3892\/br.2024.1732","article-title":"Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: A systematic review and meta\u2212analysis of randomized controlled trials","volume":"20","author":"Shen","year":"2024","journal-title":"BioMed Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3109\/09537104.2012.758360","article-title":"Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient","volume":"25","author":"Andic","year":"2013","journal-title":"Platelets"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.53.151","article-title":"Portal vein thrombosis during eltrombopag treatment for immune thrombocytopenic purpura in a patient with liver cirrhosis due to hepatitis C viral infection","volume":"53","author":"Kawano","year":"2013","journal-title":"J Clin Exp Hematop"},{"key":"B7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/JBM.S80646","article-title":"Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia","volume":"7","author":"Vishnu","year":"2016","journal-title":"J Blood Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-514398","article-title":"A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia","volume":"123","author":"Bussel","year":"2014","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33615","article-title":"Risk of thromboembolism with eltrombopag: A case report of deep vein thrombosis and bilateral pulmonary embolism","volume":"15","author":"Ghumman","year":"2023","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: A review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12916-024-03537-2","article-title":"Differences in hypersensitivity reactions and gadolinium deposition disease\/symptoms associated with gadolinium exposure to gadolinium-based contrast agents: new insights based on global databases VigiBase, FAERS, and IQVIA-MIDAS","volume":"22","author":"Qu","year":"2024","journal-title":"BMC Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1512806","article-title":"Thrombotic adverse events associated with TNF-alpha blockers: a real-world pharmacovigilance analysis of the FAERS database","volume":"16","author":"Song","year":"2025","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107818","article-title":"Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database","volume":"98","author":"Li","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02713-6","article-title":"Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation","volume":"21","author":"Guo","year":"2023","journal-title":"BMC Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071752","article-title":"Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study","volume":"379","author":"Dhodapkar","year":"2022","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0322849","article-title":"Cardiovascular safety of Janus kinase inhibitors: A pharmacovigilance study from 2012-2023","volume":"20","author":"Zhong","year":"2025","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.988013","article-title":"Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.03.007","article-title":"Post-marketing safety evaluation of Vortioxetine: A decade-long pharmacovigilance study based on the FAERS database","volume":"379","author":"Wu","year":"2025","journal-title":"J Affect Disord"},{"key":"B21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12888-024-05813-0","article-title":"Exploring adverse events of Vilazodone: evidence from the FAERS database","volume":"24","author":"Jiang","year":"2024","journal-title":"BMC Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2020.1745168","article-title":"Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review","volume":"32","author":"Birocchi","year":"2020","journal-title":"Platelets"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41598-018-37012-9","article-title":"Critical roles for the phosphatidylinositide 3-kinase isoforms p110\u03b2 and p110\u03b3 in thrombopoietin-mediated priming of platelet function","volume":"9","author":"Moore","year":"2019","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58020211","article-title":"Immune thrombocytopenic purpura as a hemorrhagic versus thrombotic disease: an updated insight into pathophysiological mechanisms","volume":"58","author":"T\u0103rniceriu","year":"2022","journal-title":"Med (Kaunas)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2020.102505","article-title":"A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients","volume":"86","author":"Lozano","year":"2020","journal-title":"Blood Cells Mol Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00171.x","article-title":"Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions","volume":"28","author":"Cesari","year":"2010","journal-title":"Cardiovasc Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.653655","article-title":"A serpin with a finger in many PAIs: PAI-1\u2019s central function in thromboinflammation and cardiovascular disease","volume":"8","author":"Morrow","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1678706","article-title":"Platelet apoptosis and PAI-1 are involved in the pro-coagulant state of immune thrombocytopaenia patients treated with thrombopoietin receptor agonists","volume":"119","author":"Justo Sanz","year":"2019","journal-title":"Thromb Haemost"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15701","article-title":"Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism","volume":"20","author":"Frischmuth","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2018.12.023","article-title":"GPVI surface expression and signalling pathway activation are increased in platelets from obese patients: Elucidating potential anti-atherothrombotic targets in obesity","volume":"281","author":"BarraChina","year":"2018","journal-title":"Atherosclerosis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-022-07325-z","article-title":"Being overweight or obese is associated with an increased platelet reactivity despite dual antiplatelet therapy with aspirin and clopidogrel","volume":"37","author":"Puccini","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100774","article-title":"Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients","volume":"47","author":"van Dijk","year":"2020","journal-title":"Blood Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)45407-5","article-title":"Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids","volume":"262","author":"Lambers","year":"1987","journal-title":"J Biol Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.110.233056","article-title":"Microparticles in hemostasis and thrombosis","volume":"108","author":"Owens","year":"2011","journal-title":"Circ Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2019.1639655","article-title":"Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists","volume":"31","author":"Garabet","year":"2019","journal-title":"Platelets"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160563","article-title":"Platelet apoptosis in adult immune thrombocytopenia: insights into the mechanism of damage triggered by auto-antibodies","volume":"11","author":"Goette","year":"2016","journal-title":"PloS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221076812","article-title":"A thrombopoietin receptor agonist to rescue an unusual platelet transfusion-induced reaction in a p.V1316M-associated von Willebrand disease type 2B patient","volume":"13","author":"Casari","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102342","article-title":"Thrombosis in patients with immune thrombocytopenia: incidence, risk, and clinical outcomes","volume":"8","author":"Goncalves","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.109109","article-title":"The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP","volume":"241","author":"Saldanha","year":"2024","journal-title":"Thromb Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/17474086.2024.2318345","article-title":"Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management","volume":"17","author":"Provan","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103581","article-title":"Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A systematic review and meta-analysis","volume":"171","author":"Tjepkema","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter","year":"2013","journal-title":"Br J Haematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/phar.70075","article-title":"Thromboembolic risk of thrombopoietin receptor agonists for adult primary immune thrombocytopenia: A systematic review and meta-analysis integrating randomized controlled trials and prospective evidence","volume":"45","author":"Dai","year":"2025","journal-title":"Pharmacotherapy"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100125","article-title":"Catastrophic antiphospholipid syndrome in an immune thrombocytopenia patient treated with avatrombopag","volume":"7","author":"Van de Vondel","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1527554","article-title":"Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1669486\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:39:49Z","timestamp":1770964789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1669486\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2026.1669486"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1669486","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"1669486"}}